RAPT Therapeutics Analyst Ratings
Wolfe Research: Downgraded RAPT Therapeutics (RAPT.US) rating from superior to market to Peer Perform.
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
Barclays: The RAPT Therapeutics (RAPT.US) rating was lowered from an increase in holdings to a wait-and-see rating, and the target price was adjusted from $13.00 to $4.00.
Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4
Maintaining Hold Rating on RAPT Therapeutics Amid Clinical Uncertainties and Financial Outlook
Guggenheim: Downgraded RAPT Therapeutics (RAPT.US) rating from buy to neutral.
RAPT Therapeutics Analyst Ratings
Maintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertainty
RAPT Therapeutics Analyst Ratings
HC Wainwright & Co. : Reiterates RAPT Therapeutics (RAPT.US) neutral rating.
RAPT Therapeutics Analyst Ratings
Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns
Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)
UBS Downgrades RAPT Therapeutics to Neutral, Lowers Price Target to $10
H.C. Wainwright Cuts RAPT to Neutral, Cites Delays Due to Clinical Hold
RAPT Therapeutics Analyst Ratings
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target Is $15
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Universal Health (UHS) and RAPT Therapeutics (RAPT)
RAPT Therapeutics Analyst Ratings
No Data